指南与共识药物相互作用

基于临床数据解读细胞色素P-450抑制与诱导效应:现行标准与实施建议

Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation.
指南 / 共识 · Clin Pharmacol Ther · 2020-06-20

该综述阐述了将改变CYP酶活性的药物归类为强、中、弱抑制剂或诱导剂的现行半定量标准,总结了导致分类模糊或不一致的常见情形,并提出在数据不确定时解读与应用现行标准的方法;该方法应用于超过1000项CYP审评时,几乎在所有案例中都能明确分类。

要点

  • CYP抑制剂/诱导剂分类基于临床研究中底物暴露变化的幅度,标准简单且半定量。
  • 分类受数据局限、研究结果不一致等因素影响,可能导致临床药物相互作用管理差异。
  • 低估或高估相互作用潜力均可引发有害的临床决策,如剂量调整不当或回避最优治疗。

核心结论

  • CYP抑制剂和诱导剂的分类标准简单半定量,但实际归类常因数据局限和研究不一致而模糊。
  • 分类模糊可能导致临床药物相互作用管理出现有害差异,需在不确定性下审慎解读数据。
  • 所提出的数据解读方法应用于超过1000项CYP审评时,几乎在所有案例中均能明确分类。

研究设计与样本

  • 综述类文章,检索范围未在摘要中报告。

主要发现

  • 改变CYP酶活性的药物根据临床研究中底物暴露影响幅度被分为强、中、弱抑制剂或诱导剂。
  • 已发表数据的局限性、研究结果不一致及其他因素常使药物归类复杂化。
  • 低估相互作用潜力(如将中等效应归为弱)可能导致临床对真实风险应对不足或忽视潜在相互作用。
  • 高估相互作用潜力可能导致底物剂量过度调整或不必要地回避最优治疗。

关键数值与推荐

  • CYP抑制剂和诱导剂分类标准为简单半定量,基于临床研究中底物暴露变化的幅度。
  • 药品标签可能推荐避免与强抑制剂合用,与中等抑制剂合用时减量。

临床怎么用

  • 临床应依据CYP抑制剂/诱导剂的分类制定药物相互作用管理推荐,如避免合用或调整剂量。
  • 在分类不确定时,应采用文中提出的数据解读方法,审慎评估相互作用风险。

局限性

  • 摘要未报告综述的检索范围及纳入研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Agents that modify cytochrome P-450 (CYP) enzyme activity are characterized as strong, moderate, or weak inhibitors or inducers based on the magnitude of their impact on substrate exposure in clinical studies. Criteria for these classifications are simple and semiquantitative. However, assignment of a given agent to a CYP inhibitor or inducer category is often complicated by limitations of the published data, inconsistent study findings, and other factors. CYP inhibitor and inducer categories are commonly used as a basis for differentiating drug interaction management recommendations. For example, product labeling for a CYP substrate may recommend avoidance in combination with strong inhibitors and dose reduction in combination with moderate inhibitors. When such recommendations exist, ambiguity or variability in placement of inhibitors or inducers into categories can introduce potentially harmful variations in clinical drug interaction management. Failure to adequately reflect the drug interaction potential of an agent by under-categorizing it (e.g., calling it weak when data point to moderate effects), for example, may lead clinicians to respond inadequately to real risks, or to ignore potential interactions altogether. Over-categorization may lead to actions such as over-adjustment of substrate doses or unnecessary avoidance of optimal treatments. This review describes the current criteria for assignment of CYP inhibitor and inducer categories, summarizes common circumstances leading to ambiguous or variable CYP inhibitor and inducer categorizations, and proposes an approach to data interpretation and application of current criteria under uncertainty. When applied to > 1,000 CYP reviews, the approach described has identified a clear categorization in almost all cases.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stout SM, Nemerovski CW, Streetman DS, et al. Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation. Clin Pharmacol Ther. 2020. PMID: 32452536. doi:10.1002/cpt.1918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。